Lactobacillus Reuteri in Children With Constipation
Recruitment status was: Recruiting
The most common cause of children chronic constipation is functional disorders. Functional constipation is diagnosed after excluding organic causes of constipation (anatomical, neurological, endocrinological) and identification of two symptoms defined by the Rome III criteria. There could be low number of bowel movements (below three times a week), defecation pain, fecal incontinence (once a week), stool consistency or occurrence of large diameter stools. The treatment is change of diet, defecation training and application of laxatives.
The probiotics are defined as living microorganisms, which provided in a proper doses should result in beneficial effect on a host health. The assessment of its characteristic is related to strain of bacteria affiliation.
Taking into the consideration that patients with constipation may experience microflora intestine disorders, using the probiotics can have the positive impact on process of treating this disease. The additional reason for using the probiotics during the constipation treatment is an influence of probiotics on movement of the alimentary canal.
In spite of proved effectiveness of some probiotics' strains further research are required, because clinical significance is ambiguous and the effect is confirmed among patients with short medical history. That's way the further analysis of probiotic Lactobacillus reuteri DSM 17938, which was successful treatment method of chronic constipation amongst children (infants) should be performed.
The primary aim of the study is the assessment of Lactobacillus reuteri DSM 17938 efficacy, provided with macrogol (Forlax), as treatment of constipation in 3-7 years old children. The baseline of estimation is the frequency comparison of bowel movement in children belonging into two groups: Lactobacillus reuteri treatment and placebo.
The secondary aim of the study is the assessment of frequency the additional symptoms connected with defecation disorders: such as: number of pain episodes during defecation, the intensity of pain, number of hard stools, number of fecal incontinence per week, number of macrogol (Forlax) pockets used.
The investigators believe that constipation treatment (laxatives- macrogol) with Lactobacillus reuteri has better efficacy that the same treatment without Lactobacillus reuteri in 3-7 years old children with medical history of chronic constipation.
|Functional Constipation||Dietary Supplement: Lactobacillus reuteri DSM 17938 Dietary Supplement: Placebo||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
|Official Title:||The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial|
- Number of bowel movement per week, without fecal incontinence [ Time Frame: 12 weeks ]
- The number of bowel movements per week [ Time Frame: 12 weeks ]Other secondary items are: the number of pain episodes during defecation per week, the number of hard stools, the number of fecal incontinence per week, the number of patients who have to change amount of drug or use of enema.
- The number of pain episodes during defecation per week, [ Time Frame: 12 weeks ]
- The number of hard stools [ Time Frame: 12 weeks ]
- The number of fecal incontinence per week [ Time Frame: 12 weeks ]
- The number of patients who have to change amount of drug [ Time Frame: 12 weeks ]
- The number of patients who have to change use of enema. [ Time Frame: 12 weeks ]
|Study Start Date:||July 2011|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
|Placebo Comparator: Placebo||
Dietary Supplement: Placebo
Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
Active Comparator: Probiotics
Lactobacillus reuteri DSM 17938
Dietary Supplement: Lactobacillus reuteri DSM 17938
Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10^8CFU).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01388712
|Contact: Jaroslaw Kierkus, Ph.D.||+48 228157384|
|Warsaw, Poland, 04-730|
|Contact: Jaroslaw Kierkus, Ph.D. +48 228157384|
|Study Chair:||Jaroslaw Kierkus, Ph.D.||Children's Memorial Health Institute, Poland|
|Principal Investigator:||Agnieszka Wegner, M.D.||Children's Memorial Health Institute, Poland|